Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protocol: Adjuvant Belzutifan with Pembrolizumab for Renal Cell Carcinoma
In the LITESPARK-022 trial, adjuvant pembrolizumab plus belzutifan significantly improved disease-free survival compared to pembrolizumab plus placebo in patients with resected cle
New Reference: Neoadjuvant Paclitaxel with Trastuzumab and Pertuzumab for HER2-Positive Breast Cancer
This secondary analysis of the DAPHNe nonrandomized clinical trial showed excellent long-term outcomes with neoadjuvant THP in patients with early-stage ERBB2-positive breast cance
New Drug: Mezigdomide with Carfilzomib – Dexamethasone for Multiple Myeloma
The SUCCESSOR-2 trial evaluated the efficacy and safety of mezigdomide in combination with carfilzomib and dexamethasone versus carfilzomib plus dexamethasone in patients with rela
New Indication: Adjuvant Ensartinib for Resected ALK-Positive NSCLC
In patients with completely resected stage IB to IIIB ALK-positive non-small cell lung cancer, ensartinib significantly increased the percentage of patients alive and disease-free
New Protocol: Neoadjuvant Durvalumab with Dose-Dense MVAC for Bladder Cancer
The NEMIO study investigated neoadjuvant ddMVAC combined with durvalumab with or without tremelimumab in patients with muscle-invasive bladder cancer. The pathologic complete respo
New Reference: Oral Decitabine and Venetoclax for Newly Diagnosed AML
In this phase 1-2 trial, an all-oral regimen of decitabine-cedazuridine plus venetoclax was evaluated for newly diagnosed acute myeloid leukemia in patients ineligible for intensiv
New Drug: Aumolertinib for EGFR-Mutated NSCLC
The AENEAS2 study demonstrated that aumolertinib combined with chemotherapy significantly improved progression-free survival compared to aumolertinib monotherapy in patients with E
New Protocol: Perioperative Serplulimab with Chemotherapy for PD-L1 Positive Gastric Cancer
This phase 3 study demonstrated that neoadjuvant serplulimab plus chemotherapy followed by adjuvant serplulimab significantly improved event-free survival compared with perioperati
New Protocol: Sacituzumab Tirumotecan with Pembrolizumab for PD-L1 Positive Advanced NSCLC
The OptiTROP-Lung05 phase 3 trial demonstrated that sacituzumab tirumotecan combined with pembrolizumab significantly improved progression-free survival and objective response rate
